<DOC>
	<DOCNO>NCT00452881</DOCNO>
	<brief_summary>Oxaliplatin manageable toxicity profile cisplatin , renal toxicity lower incidence hematological gastrointestinal toxicity . The combination gemcitabine-oxaliplatin attractive NSCLC patient may improve therapeutic index . Given potential advantage oxaliplatin th find addition chemotherapy improve survival postoperative adjuvant setting , conduct phase II trial compare adjuvant gemcitabine-oxaliplatin gemcitabine-cisplatin patient completely resect stage IB , II IIIA NSCLC</brief_summary>
	<brief_title>Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin Completely Resected Stage IB/II/IIIA NSCLC</brief_title>
	<detailed_description>This study randomize phase II study . Patients randomize 1 2 treatment arm : patient receive adjuvant chemotherapy gemcitabine-oxaliplatin gemcitabine-cisplatin . Chemotherapy start within 8 week complete surgical resection . Patients follow every 3 month 2 year , every 6 month 3 year . Gemcitabine-Oxaliplatin ( GemOx ) chemotherapy : Gemcitabine ( 1,250 mg/m2 ) +Oxaliplatin ( 85 mg/m2 ) give day 1 15 q 4weeks . maximum 4 cycle . Gemcitabine-Cisplatin ( GemCis ) chemotherapy : Gemcitabine ( 1,250 mg/m2 ) + Cisplatin ( 40 mg/m2 ) give day 1 15 q 4weeks . maximum 4 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologic diagnosis nonsmall cell lung cancer . 2 . Presence pathological stage IB , II IIIA , accord American Joint Committee Cancer ( AJCC ) . 3 . Completely resected tumor NCC hospital . 4 . No prior tumor therapy ( radiotherapy , chemotherapy , immunotherapy , type tumor therapy ) . 5 . Performance status 01 ECOG scale . 6 . At least 18 year old 7 . Patient compliance allow adequate followup . 8 . Adequate organ function include follow : Adequate hematologic function : WBC count ≥ 4,000/uL , absolute neutrophil count ( ANC ) ≥ 1,500/uL , platelet count ≥ 100,000/uL , hemoglobin ³ 10 gm/dL.Adequate hepatic function : bilirubin ≤ 1.5 x UNL , ALT AST ≤ 2.5 x UNL.Adequate renal function : creatinine ≤ 1.5mg/dL . 9 . Signed informed consent patient legal representative . 10 . Patients reproductive potential must use approved contraceptive method 3 month study . Females childbearing potential must negative urine hCG test within 7 day prior study enrollment . 1 . Concurrent administration tumor therapy , include radiotherapy , chemotherapy , immunotherapy . 2 . Active uncontrolled infection . 3 . Serious concomitant disorder would compromise safety patient compromise patient 's ability tolerate therapy . 4 . Second primary malignancy . 5 . Significant neurological mental disorder . 6 . Pregnant nursing . 7 . MI within precede 6 month symptomatic heart disease include unstable angina , congestive heart failure , uncontrolled arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
</DOC>